Chimeric Botulinum Neurotoxin for Targeted CGRP Pain Blockade

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Conventional treatments for pain, such as CGRP-associated pain, are associated with numerous side effects and do not effectively block pain mediators at the point of release, necessitating a need for improved therapeutics with fewer side effects and targeted pain inhibition.

Innovation Solution

A chimeric clostridial neurotoxin comprising a botulinum neurotoxin A (BoNT/A) light-chain and translocation domain, and a BoNT/B receptor binding domain, is developed to bind to Aδ or C nerve fibers, inhibiting the release of pain mediators like CGRP by cleaving SNAP25, thereby providing selective blockade and reducing side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional pain treatments (monoclonal antibodies, small-molecule antagonists) are used to block pain mediators, then pain relief is achieved, but numerous side effects occur and the mediators are not blocked at the point of release

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The chimeric clostridial neurotoxin performs preliminary action by binding to and cleaving SNAP25 on Aδ or C nerve fibers before pain mediators can be released. This prevents the mediators from reaching their target receptors, thereby blocking pain transmission at the point of release rather than attempting to block already-released mediators, which reduces side effects while maintaining pain relief effectiveness

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The chimeric clostridial neurotoxin acts as an intermediary substance that interferes with the pain transmission pathway. By cleaving SNAP25, it disrupts the release mechanism of pain mediators, serving as a mediating agent that prevents direct interaction between pain mediators and their receptors, thus achieving pain relief with fewer side effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If conventional pain treatments are used, then pain mediators are blocked, but the blockade is not at the point of release and therapeutic action is limited

Engineering Contradiction:

Improvepain mediator blockingVSAvoidtherapeutic action duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

By cleaving SNAP25, the chimeric clostridial neurotoxin creates a persistent disruption in the pain mediator release mechanism. This continuous blockade at the point of release maintains therapeutic action throughout the duration of the toxin's effect, providing prolonged pain relief compared to conventional treatments that only block mediators after release

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The chimeric clostridial neurotoxin effectively inhibits pain mediator release with fewer side effects, offering prolonged therapeutic action and targeted pain relief, particularly effective in treating migraine and CGRP-associated pain.

Implementation Method 1

inhibiting the release of pain mediators like CGRP by cleaving SNAP25

Methodology Applied

Scientific EffectProteolytic cleavage:

Data Source

PatentUS20260021170A1Treatment of pain

Publication Date: 2026.01.22 IPSEN BIOPHARM LTD

AI summary

The present invention is directed inter alia to the treatment of pain. For example, there is provided a chimeric clostridial neurotoxin for use in treating pain by inhibiting the release of a pain mediator from a neuron comprising an Aδ nerve fiber or a C nerve fiber, wherein the chimeric clostridial neurotoxin binds to the neuron comprising the Aδ nerve fiber or the C nerve fiber, respectively, and wherein the chimeric clostridial neurotoxin comprises a botulinum neurotoxin A (BoNT/A) light-chain and translocation domain (HN domain), and a BoNT/B receptor binding domain (HC domain). Also provided are methods, uses, kits, and unit dosage forms.